Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...

Biopharma company Halozyme Therapeutics is on a mission to replace IV-drug delivery. It develops subcutaneous devices to make it easier and quicker to inject high-volume drugs into patients. Halozyme ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...

TG Therapeutics' stock rose 15% since my November buy recommendation, driven by Briumvi's strong performance and strategic ...

UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX® (bimekizumab-bkzx) is now available. These ...

The announcement that inhaled insulin will soon be available in India has understandably generated a lot of excitement and ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) today and set a price target of ...

Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, ...

The Food and Drug Administration (FDA) has issued a “Dear Veterinarian Letter” regarding reports of adverse events in dogs ...

Shares of Serina Therapeutics were trading higher after hours following the company's announcement it sold its UniverXome subsidiary in a deal which was finalized on Dec. 23. After the bell, the ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's ...

The substantial data supporting platelet-rich plasma (PRP) therapy and exosomes for androgenic alopecia have yet to convince ...